Please enable JavaScript.
Coggle requires JavaScript to display documents.
homonal osteoporosis drugs (Raloxifene (Evista) (mechanism action…
homonal osteoporosis drugs
Raloxifene (Evista)
mechanism action
Raloxifene binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Raloxifene produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women, thus slowing the rate of bone loss
indications
treatment and prevention of osteoporosis in postmenopausal women
reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.
contraindication
lactating women, women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.,
side effect
vomiting, stomach pain, or. runny or stuffy nose, stroke or serious blood clots to form in the legs, lungs, or eyes.
storage conditions
should be stored at room temperature
root of administration
administered orally
Abalopraratide
mechanism of action
. Abolaparatide-SC is a synthetic peptide analogue of human parathyroid hormone-related protein (hPTHrP), which interacts with parathyroid receptor 1 and exhibits anabolic actions to regulate the bone formation.
indications
treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
contraindications
Orthostatic hypotension,Hypercalcemia, hyperparathyroidism, Renal failure, renal impairment, Hypercalciuria, nephrolithiasis
side effect
high calcium levels in the urine (hypercalciuria), dizziness,nausea, headache, palpitations
root of administration
subcutaneous administration
storage condition
Store at room temperature: Store at 15°-25°C.
Denosumab
Mechanism action
Denosumab is a fully human monoclonal antibody that binds RANKL, preventing RANKL from activating RANK, its receptor on the osteoclast surface (11). With reduced RANK–RANKL binding, osteoclast formation, function and survival are inhibited, bone resorption decreases and bone mass increases (11–13).
indications
high risk for fracture,history of osteoporotic fracture patients who have failed or are intolerant to other therapy,
side effect
Low calcium levels,Infections,Rash, Sweating, Lower back and leg pain, Constipation, Damage to the jaw bone
contraindications
anaphylaxis,facial swelling/angioedema, hypotension, pruritus, and urticaria.
storage conditions
Keep the container in the outer carton in order to protect from light., stored at room temperature (up to 25°C) for up to 30 days in the original containe
root of administration
Oral administration
Teriparatide
mechanism action
Mechanism of action. Teriparatide is a portion of human parathyroid hormone (PTH), amino acid sequence 1 through 34, of the complete molecule (containing 84 amino acids). ... Thus, chronically elevated PTH will deplete bone stores. However, intermittent exposure to PTH will activate osteoblasts more than osteoclasts.
contraindications
restricted to men and women with severe osteoporosis,high risk of a fracture
side effect
a light-headed feeling, like you might pass out, leg cramps, headaches, dizziness, high blood calcium and high urinary calcium
indications
premenopausal women
root of administration
intravenous injection
storage conditions
stored under refrigeration at 2° to 8°C